Prevention of Stroke in Atrial Fibrillation After Coronary Stenting: Systematic Review and Network Meta-Analysis

被引:4
作者
Knijnik, Leonardo [1 ]
Rivera, Manuel [4 ]
Blumer, Vanessa [5 ]
Cardoso, Rhanderson [6 ]
Fernandes, Amanda [1 ]
Fernandes, Gilson [1 ]
Ferreira, Tanira [1 ]
Romano, Jose G. [3 ]
Lambrakos, Litsa K. [2 ]
Cohen, Mauricio G. [2 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Internal Med, 1611 NW 12th Ave,Suite 601, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Dept Med, Cardiovasc Div, Coral Gables, FL 33124 USA
[3] Univ Miami, Miller Sch Med, Dept Neurol, Coral Gables, FL 33124 USA
[4] Washington Univ, Sch Med, Cardiovasc Div, St Louis, MO 63110 USA
[5] Duke Univ Hosp, Cardiovasc Div, Durham, NC USA
[6] Johns Hopkins Med Inst, Div Cardiol, Baltimore, MD 21205 USA
关键词
atrial fibrillation; fibrinolytic agents; humans; percutaneous coronary intervention; stroke; TRIPLE ANTITHROMBOTIC THERAPY; DUAL ANTIPLATELET THERAPY; ACUTE MYOCARDIAL-INFARCTION; ORAL ANTICOAGULATION; RANDOMIZED-TRIAL; INTERVENTION; RISK; IMPLANTATION; CLOPIDOGREL; DABIGATRAN;
D O I
10.1161/STROKEAHA.119.026078
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose- The optimal antithrombotic strategy to balance thromboembolic and bleeding events, especially acute stroke, for patients with atrial fibrillation following coronary stenting remains a matter of debate. We conducted a network meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in atrial fibrillation after coronary stenting. Methods- PubMed, Scopus, and Cochrane Central were searched for randomized controlled trials and observational studies of patients with atrial fibrillation after coronary stenting. The outcomes of interest were stroke, myocardial infarction, major adverse cardiac events, mortality, and major bleeding. A network meta-analysis was performed comparing the available antithrombotic regimens in the literature. Results- Three randomized and 15 observational studies were included, with a total of 23478 participants. Median follow-up was 2 years. Network meta-analysis demonstrated that vitamin K antagonist plus single antiplatelet therapy or direct-acting oral anticoagulant plus single antiplatelet therapy were the most effective regimens in preventing stroke. Direct-acting oral anticoagulant regimens were associated with lower major bleeding rates than vitamin K antagonist regimens. Regimens with dual antiplatelet therapy were associated with lower rates of myocardial infarction. Vitamin K antagonist plus dual antiplatelet therapy was associated with a lower mortality and low-dose direct-acting oral anticoagulants with decreased major cardiovascular adverse events. Conclusions- Direct-acting oral anticoagulant regimens were associated with less major bleeding and major cardiovascular adverse events, but vitamin K antagonists were associated with decreased mortality and stroke. These results suggest that the decision of antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention needs to be individualized.
引用
收藏
页码:2125 / 2132
页数:8
相关论文
共 52 条
  • [1] [Anonymous], PLOS ONE
  • [2] Risk and Benefits of Triple Therapy in Patients Undergoing Coronary Stent Implantation Requiring Oral Anticoagulation: A Meta-Analysis of 16 Studies
    Barbieri, Lucia
    Verdoia, Monica
    Schaffer, Alon
    Suryapranata, Harry
    De Luca, Giuseppe
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2016, 30 (06) : 611 - 622
  • [3] Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention
    Batra, Gorav
    Friberg, Leif
    Erlinge, David
    James, Stefan
    Jernberg, Tomas
    Svennblad, Bodil
    Wallentin, Lars
    Oldgren, Jonas
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (01) : 36 - 45
  • [4] Triple anticoagulation therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention - real life assessment
    Bogacki, Pawel
    Kablak-Ziembicka, Anna
    Bryniarski, Krzysztof
    Wrotniak, Leszek
    Ostrowska-Kaim, Elibieta
    Zmudka, Krzysztof
    Przewlocki, Tadeusz
    [J]. POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2016, 12 (04): : 303 - 313
  • [5] Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
    Cannon, Christopher P.
    Bhatt, Deepak L.
    Oldgren, Jonas
    Lip, Gregory Y. H.
    Ellis, Stephen G.
    Kimura, Takeshi
    Maeng, Michael
    Merkely, Bela
    Zeymer, Uwe
    Gropper, Savion
    Nordaby, Matias
    Kleine, Eva
    Harper, Ruth
    Manassie, Jenny
    Januzzi, James L.
    ten Berg, Jurrien M.
    Steg, Gabriel
    Hohnloser, Stefan H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (16) : 1513 - 1524
  • [6] Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities Don't Throw Out the Baby With the Bath Water
    Capodanno, Davide
    Angiolillo, Dominick J.
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (11) : 1086 - 1088
  • [8] Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation A systematic review and meta-analysis of observational studies
    Chaudhary, Nabin
    Bundhun, Pravesh Kumar
    Yan, He
    [J]. MEDICINE, 2016, 95 (50) : e5581
  • [9] Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents
    Choi, Hyo-In
    Ahn, Jung-Min
    Kang, Se Hun
    Lee, Pil Hyung
    Kang, Soo-Jin
    Lee, Seung-Whan
    Kim, Young-Hak
    Lee, Cheol Whan
    Park, Seong-Wook
    Park, Duk-Woo
    Park, Seung-Jung
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (11) : E107 - 1085
  • [10] Cullell Natalia, 2018, Oncotarget, V9, P29238, DOI 10.18632/oncotarget.25579